
AKLI
Healthcare · Health Information Services · $34.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 9, 2024 | Time not confirmed | -0.17 | -0.12 | +29.4% |
| Feb 29, 2024 | After the close | -0.21 | -0.14 | +32.2% |
| Nov 9, 2023 | After the close | -0.19 | -0.18 | +5.3% |
| Aug 10, 2023 | After the close | -0.20 | -0.16 | +20.0% |
| May 11, 2023 | After the close | -0.22 | -0.21 | +3.9% |
| Mar 7, 2023 | After the close | -0.31 | -0.72 | -132.3% |
| Nov 10, 2022 | After the close | -0.25 | 0.76 | +404.0% |
| Aug 12, 2022 | After the close | — | -0.37 | — |
| May 16, 2022 | After the close | — | -0.13 | — |
| Mar 23, 2022 | After the close | — | -0.06 | — |
| Nov 15, 2021 | Time not confirmed | — | -0.01 | — |
| Jul 1, 2021 | Time not confirmed | — | -0.01 | — |
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers…